Tempus AI, Inc. (TEM) Revenue CAGR:69.82%(TTM)
Revenue CAGR uses precomputed financial statement history.
Over longer horizons, Tempus AI, Inc.'s Revenue CAGR averages 58.57% over 3 years and 42.06% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Revenue CAGR measures how Tempus AI, Inc.'s top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
TEM Revenue CAGR Chart
Tempus AI, Inc. (TEM)
TEM Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 18 quarters.
TEM Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $693.40M | $1.27B | +$578.39M | +83.41% | +83.41% |
| 2024 | $531.82M | $693.40M | +$161.58M | +30.38% | +30.38% |
| 2023 | $320.67M | $531.82M | +$211.15M | +65.85% | +65.85% |
| 2022 | $257.85M | $320.67M | +$62.81M | +24.36% | +24.36% |
| 2021 | $188.00M | $257.85M | +$69.85M | +37.15% | +37.15% |
| 2020 | $62.06M | $188.00M | +$125.95M | +202.95% | +202.95% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $348.12M | -5.2% | +36.1% |
| Q4 2025 | $367.21M | +9.9% | +83.0% |
| Q3 2025 | $334.21M | +6.2% | +84.7% |
| Q2 2025 | $314.63M | +23.0% | +89.6% |
| Q1 2025 | $255.74M | +27.4% | +75.4% |
| Q4 2024 | $200.68M | +10.9% | +35.8% |
| Q3 2024 | $180.93M | +9.0% | +33.0% |
| Q2 2024 | $165.97M | +13.8% | +25.3% |
| Q1 2024 | $145.82M | -1.3% | +26.1% |
| Q4 2023 | $147.72M | +8.6% | +46.8% |
| Q3 2023 | $136.06M | +2.7% | +85.6% |
| Q2 2023 | $132.42M | +14.5% | +152.5% |
| Q1 2023 | $115.62M | +14.9% | +75.1% |
| Q4 2022 | $100.63M | +37.3% | +52.4% |
| Q4 2021 | $73.31M | +39.8% | -27.3% |
| Q3 2021 | $52.45M | -20.6% | +3.4% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky